NVS : Summary for Novartis AG Common Stock - Yahoo Finance

U.S. Markets close in 6 hrs 14 mins

Novartis AG (NVS)

NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
68.31-0.65 (-0.94%)
As of 9:46 AM EST. Market open.
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close68.96
Bid68.69 x 1000
Ask68.74 x 7000
Day's Range68.30 - 68.75
52 Week Range67.28 - 88.49
Avg. Volume2,742,350
Market Cap163.58B
PE Ratio (TTM)24.09
Earnings DateN/A
Dividend & Yield2.72 (3.99%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Sanofi May Battle Johnson & Johnson For European Biotech Actelion
    Investor's Business Daily17 hours ago

    Sanofi May Battle Johnson & Johnson For European Biotech Actelion

    Sanofi is mulling a bid for Actelion, which has an offer from Johnson & Johnson on the table.

  • Reutersyesterday

    Novartis' drug tops chemotherapy in untreated lung cancer patients

    Novartis AG said its cancer drug, Zykadia, was twice as effective as chemotherapy in slowing the progression of a rare form of lung cancer in a late-stage study. Patients with anaplastic lymphoma kinase-positive (ALK+)advanced non-small cell lung cancer treated with Zykadia had a median progression-free survival of 16.6 months, compared to 8.1 months for those on chemotherapy. Novartis' drug also has conditional approval as a second-line treatment in Europe.

  • Reutersyesterday

    Exclusive: Novartis in talks to sell some central nervous system drugs - sources

    Novartis is in talks about the sale of some older neuroscience drugs, people close to the matter said, as the Swiss drugmaker clears the decks to concentrate on promising new medicines it hopes will help to restore sales growth. Novartis did not immediately return phone calls and emails seeking comment. Chief Executive Joe Jimenez is in the process of refreshing the group's drugs portfolio to help return the company to sales growth.